Doryx without
StreetInsider.com - Impax Confirms Patent Lawsuit Relating to Doryx(R) Tablets 150 mgMorning Movers 4/24: DDR, SUMT, F, CHRT, ZGEN Higher; UCBH, IBKR, BLUD, IBCP, COLM Lower HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that Warner Chilcott Laboratories Ireland Limited, Warner Chilcott Company, Inc., Warner Chilcott (US), LLC, and Mayne Pharma International Pty. Ltd. filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in response to Impax's challenge of the patent listed in connection with Doryx(R) (doxycycline hyclate) delayed-release tablets, 150 mg. Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities.